However, the strongest recommendation is for sodium–glucose cotransporter 2 (SGLT2) inhibitors and the evidence supporting the use of SGLT2 inhibitors has been strengthened by the results of the DELIVER (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure) trial.2, 3, 4, 5, 6. The gene discussed is SLC5A2; the disease is heart failure.